Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
Intrathecal Allogeneic B7-H3-Targeted CAR γδ T Cells for Leptomeningeal Metastasis from Solid Tumors: Safety, Efficacy, and Immunologic Dynamics in a Phase I Trial.
СтатьяКлиническое исследование I фазыНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ma Peiwen, Zhou Yongxin, Ma Weiwei, Wang Yuning, Cai Hongqing, Sui Yinqiang, Zhao Lina, Zhang Yonghui, Wang Shuhang, Li Ning
Аннотация
PURPOSE: To evaluate intrathecal QH104, an allogeneic B7 homolog 3 (B7-H3)-targeted chimeric antigen receptor (CAR) γδ T-cell therapy, in patients with leptomeningeal metastasis (LM).
PATIENTS AND METHODS: In this phase I study (NCT06592092), 3 patients with LM from B7-H3-positive solid tumors were enrolled, including 2 with lung adenocarcinoma and 1 with triple-negative breast cancer. QH104 was administered at a fixed dose of 3 × 107 cells per infusion via lumbar puncture or an Ommaya reservoir. The primary objective was to evaluate clinical response. Secondary objectives included safety, overall survival, quality of life, and pharmacokinetic/pharmacodynamic profiling.
RESULTS: QH104 was generally well tolerated, with no grade ≥ 4 treatment-related adverse events (TRAE). One patient developed grade 3 immune effector cell-associated neurotoxicity syndrome. All TRAE resolved with supportive care. All patients had stable disease on days 14 and 30 according to the Response Assessment in Neuro-Oncology Leptomeningeal Metastases criteria, with symptom improvement in 2 patients. Cerebrospinal fluid (CSF) cytology converted to and remained negative through day 30 in 1 patient with positive baseline cytology. B7-H3-CAR γδ T cells persisted in CSF for at least 1 week and were accompanied by increased interferon (IFN) γ levels. Single-cell sequencing suggested IFNγ-associated immune remodeling in CSF, including expansion of an inflammatory macrophage state and subsequent lymphocyte recruitment.
CONCLUSIONS: This study provides preliminary proof of concept for intrathecal allogeneic B7-H3-CAR γδ T-cell therapy in LM, with early evidence of safety, clinical activity, local persistence, and IFNγ-associated immune remodeling in CSF.
PATIENTS AND METHODS: In this phase I study (NCT06592092), 3 patients with LM from B7-H3-positive solid tumors were enrolled, including 2 with lung adenocarcinoma and 1 with triple-negative breast cancer. QH104 was administered at a fixed dose of 3 × 107 cells per infusion via lumbar puncture or an Ommaya reservoir. The primary objective was to evaluate clinical response. Secondary objectives included safety, overall survival, quality of life, and pharmacokinetic/pharmacodynamic profiling.
RESULTS: QH104 was generally well tolerated, with no grade ≥ 4 treatment-related adverse events (TRAE). One patient developed grade 3 immune effector cell-associated neurotoxicity syndrome. All TRAE resolved with supportive care. All patients had stable disease on days 14 and 30 according to the Response Assessment in Neuro-Oncology Leptomeningeal Metastases criteria, with symptom improvement in 2 patients. Cerebrospinal fluid (CSF) cytology converted to and remained negative through day 30 in 1 patient with positive baseline cytology. B7-H3-CAR γδ T cells persisted in CSF for at least 1 week and were accompanied by increased interferon (IFN) γ levels. Single-cell sequencing suggested IFNγ-associated immune remodeling in CSF, including expansion of an inflammatory macrophage state and subsequent lymphocyte recruitment.
CONCLUSIONS: This study provides preliminary proof of concept for intrathecal allogeneic B7-H3-CAR γδ T-cell therapy in LM, with early evidence of safety, clinical activity, local persistence, and IFNγ-associated immune remodeling in CSF.